Appeals Court Affirms Pfizer Marketing Exclusivity For Diflucan
The U.S. Court of Appeals for the District of Columbia has upheld a lower court's decision that extends Pfizer's U.S. marketing exclusivity for blockbuster antifungal drug Diflucan until late July....To view the full article, register now.
Already a subscriber? Click here to view full article